Shandong Buchang Pharmaceuticals 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Chao Zhao

최고 경영자

CN¥2.4m

총 보상

CEO 급여 비율	n/a
CEO 임기	23.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	14.8yrs
이사회 평균 재임 기간	12.7yrs

최근 관리 업데이트

Recent updates

The Market Doesn't Like What It Sees From Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues Yet

Aug 26

Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

Jul 29

Why Investors Shouldn't Be Surprised By Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Low P/S

Apr 27

We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

Feb 28

CEO

Chao Zhao (57 yo)

23.8yrs

테뉴어

CN¥2,439,600

보상

Mr. Chao Zhao serves as the President and Director of Shandong Buchang Pharmaceutical Co., Ltd. since 2001 and served as its General Manager since 2001. Mr. Zhao serves as Executive Director and General Ma...

리더십 팀

이름	위치	테뉴어	보상	소유권
Chao Zhao	President & Director	23.8yrs	CN¥2.44m	데이터 없음
Yi Min Wang	Executive VP & Vice Chairman	12.7yrs	CN¥2.16m	데이터 없음
Ren Hui Xue	VP of Marketing & Director	14.8yrs	CN¥2.12m	데이터 없음
Xifang Wang	Chief Engineer	7.7yrs	CN¥1.11m	데이터 없음
Xiao Ping Pu	VP of Securities	13.8yrs	CN¥1.40m	데이터 없음
Zhao Buchang	Founder	no data	데이터 없음	데이터 없음
Bao Cai Wang	CFO & Director	14.8yrs	CN¥931.30k	데이터 없음
Kai Cheng	Accounting Supervisor	no data	데이터 없음	데이터 없음
Haiqin Wu	Chairman of the Academic Committee	no data	데이터 없음	데이터 없음
Wei Zhao	Vice President of Procument	no data	데이터 없음	데이터 없음

14.8yrs

평균 재임 기간

62yo

평균 연령

경험이 풍부한 관리: 603858 의 관리팀은 노련하고 경험 (평균 재직 기간 14.8 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Chao Zhao	President & Director	23.8yrs	CN¥2.44m	데이터 없음
Yi Min Wang	Executive VP & Vice Chairman	12.7yrs	CN¥2.16m	데이터 없음
Ren Hui Xue	VP of Marketing & Director	12.7yrs	CN¥2.12m	데이터 없음
Xiao Ping Pu	VP of Securities	12.7yrs	CN¥1.40m	데이터 없음
Bao Cai Wang	CFO & Director	12.7yrs	CN¥931.30k	데이터 없음
Yu Gao	Director	12.7yrs	CN¥190.50k	데이터 없음
Tao Zhao	Chairman of the Board of Directors	23.8yrs	데이터 없음	53.83% CN¥ 9.4b
Jing Zhao	Vice Chairman of the Board	12.7yrs	CN¥1.45m	데이터 없음
Ya Feng Wang	Director	12.7yrs	CN¥190.50k	데이터 없음
Chun Yi Li	Director	12.7yrs	CN¥190.50k	데이터 없음
Hua Cheng	Independent Director	3.4yrs	CN¥190.50k	데이터 없음
Ming Geng Wang	Chairman of the Supervisory Board	12.7yrs	데이터 없음	데이터 없음

12.7yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: 603858 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 12.7 년).

Shandong Buchang Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Shandong Buchang Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 28, 2024

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.076 (vs CN¥0.16 in 3Q 2023)

Shandong Buchang Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

The Market Doesn't Like What It Sees From Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Revenues Yet

Dividend of CN¥0.13 announced

Is Shandong Buchang Pharmaceuticals (SHSE:603858) Using Too Much Debt?

Shandong Buchang Pharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Shandong Buchang Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 28, 2024

First quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.41 in 1Q 2023)

Why Investors Shouldn't Be Surprised By Shandong Buchang Pharmaceuticals Co., Ltd.'s (SHSE:603858) Low P/S

Now 26% undervalued

Shandong Buchang Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Now 22% undervalued

We Think Shandong Buchang Pharmaceuticals (SHSE:603858) Is Taking Some Risk With Its Debt

Now 23% undervalued after recent price drop

Shandong Buchang Pharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) announces an Equity Buyback for CNY 360 million worth of its shares.

Third quarter 2023 earnings released: EPS: CN¥0.16 (vs CN¥0.41 in 3Q 2022)

Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) and Xi Chong agreed to acquire 14% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858),Hu Cunchao, Li Hui, and Hu Cunchao for CNY 0.

Second quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings released: CN¥1.50 loss per share (vs CN¥1.17 profit in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.30 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.49 in 2Q 2021)

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.30 (vs CN¥0.45 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.49 (vs CN¥0.54 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.37 (vs CN¥0.28 in 1Q 2020)

New 90-day low: CN¥21.37

New 90-day low: CN¥21.77

New 90-day low: CN¥23.46

New 90-day low: CN¥23.63

New 90-day low: CN¥24.21

Third quarter earnings released

Jointown Pharmaceutical Group Co., Ltd. (SHSE:600998) intends to acquire remaining 51% stake in Hubei Buchang Jiuzhoutong Pharmaceutical Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. (SHSE:603858) for CNY 21.8 million.

New 90-day low: CN¥24.81

First half earnings released

First half earnings released

Shandong Buchang Pharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령